Prostatype Genomics

Prostatype Genomics Operating Expenses

The Total Operating Expenses of Prostatype Genomics (PROGEN.ST) as of Nov 5, 2026 is 1.46 M SEK. In the previous year, Total Operating Expenses was 2.21 M SEK — a change of -33.79% (lower).

Operating Expenses

1.46 MSEK

YoY

-33.79%

Last updated:

Total Operating Expenses of Prostatype Genomics is 2025 1.46 M SEK. Total Operating Expenses of Prostatype Genomics was 2024 2.21 M SEK. It decreases by -33.79% lower compared to the previous year.

The Prostatype Genomics Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2017
9.01 M SEK
Jan 1, 2018
6.35 M SEK
Jan 1, 2020
2.41 M SEK
Jan 1, 2021
9.98 M SEK
Jan 1, 2022
17.00 M SEK
Jan 1, 2023
3.23 M SEK
Jan 1, 2024
2.21 M SEK
Jan 1, 2025
1.46 M SEK
The Prostatype Genomics Operating Expenses history
YEAROperating ExpensesYoY
1.46 MSEK-33.79%
2.21 MSEK-31.44%
3.23 MSEK-81.03%
17.00 MSEK+70.32%
9.98 MSEK+313.35%
2.41 MSEK-62.00%
6.35 MSEK-29.51%
9.01 MSEK+338.20%
2.06 MSEK-6.95%
2.21 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Prostatype Genomics Stock analysis

What does Prostatype Genomics do? Prostatype Genomics AB generates revenue by manufacturing and selling the Prostatype Test System, a comprehensive prognostic package including the Prostatype RTqPCR kit, patient database, evaluation software, and P-score accessories. The company targets clinicians and patients who require decision support for prostate cancer treatment after diagnosis, leveraging gene expression analysis of cancer cells from prostate tissue. The Prostatype Test System combines a specialized kit, database, software, and algorithm-driven data analysis to assess cancer aggressiveness and guide treatment choices. The firm's primary customers are healthcare professionals and institutions involved in prostate cancer care, utilizing the Prostatype RTqPCR kit for gene expression testing. The system's components—Prostatype RTqPCR kit, patient database, evaluation software, and P-score—are sold as an integrated solution, with the evaluation software and P-score providing algorithm-based decision support. This approach ensures clinicians receive tailored treatment recommendations based on individual patient data. Prostatype Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prostatype Genomics stock

Total Operating Expenses of Prostatype Genomics is 1.46 M SEK in 2025.

Total Operating Expenses of Prostatype Genomics changed from 2.21 M SEK to 1.46 M SEK, representing a -33.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Prostatype Genomics since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Prostatype Genomics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Prostatype Genomics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Prostatype Genomics